Nashville, TN Clinical Trials Report — June 2026

For Nashville residents considering participation in clinical research, June 2026 presents a crucial window of opportunity, particularly for trials nearing their enrollment deadlines. Across Nashville, TN, a total of 1,286 clinical trials are currently recruiting across 437 research facilities, offering diverse avenues to contribute to medical advancements.

A significant number of trials are closing soon, making prompt action essential for interested individuals. Within the next 90 days, 65 trials are slated to conclude enrollment. This urgency is particularly relevant for healthy volunteers, as 9 of these rapidly closing studies are still actively seeking participants without specific health conditions.

New Opportunities in Nashville Research

This month, Nashville saw the opening of 17 new clinical trials. While this is a slight decrease from the 21 trials that launched in May 2026, these new studies introduce important research across various medical fields.

June brings several notable new trials to Nashville, including significant Phase 2 and Phase 3 studies from major sponsors. These trials offer participants the chance to engage with cutting-edge treatments and diagnostic approaches across a range of health challenges.

• Kallyope Inc. is initiating a notable Phase 3 study, NCT07645924, "A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine." This double-blind, randomized, multicenter trial aims for 1,800 participants to evaluate the efficacy, safety, and tolerability of elismetrep compared with placebo in the acute treatment of migraine.
• Also from Kallyope Inc., NCT07674654, "A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine," is a Phase 3 study seeking 1,000 participants to evaluate the safety and tolerability of intermittent use of elismetrep for acute migraine attacks.
• Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics, is sponsoring NCT07654374, "A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)." This Phase 3, randomized, double-blind, placebo-controlled study will evaluate the long-term efficacy, safety, and tolerability of aleniglipron in 1,100 participants living with overweight or obesity and Type 2 Diabetes Mellitus over 76 weeks.
• Merck Sharp & Dohme LLC is leading NCT07634471, "A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)." This Phase 2/Phase 3 study, targeting 960 participants, investigates if the study medicine MK-1045 combined with rituximab can effectively treat follicular lymphoma.
• Convergent Genomics, Inc. is sponsoring NCT07673016, "Specimen Collection for Validation of UroAmp: A Next Generation Sequencing Platform for Detection and Surveillance of Bladder Cancer." This prospective, multicenter observational study aims to collect urine and tumor biospecimens and clinical data from 2,500 patients for bladder cancer detection and surveillance.
• Vanderbilt University Medical Center is sponsoring NCT07674758, "Modeling Mortality in Duchenne Muscular Dystrophy Cardiomyopathy: Identification of Surrogate Outcome Measures for DMD Drug Trials." This study, aiming for 1,000 participants, seeks to better understand the evolution of heart dysfunction in Duchenne and Becker Muscular dystrophy (DMD/BMD) patients and carriers.

New trials this month are exploring a range of conditions, with the most frequent being duchenne muscular dystrophy (dmd) (2 trials) and obesity (2 trials). Other conditions include advanced solid tumor (1), becker muscular dystrophy (1), bladder cancer (1), cardiomyopathy (1), carrier of duchenne muscular dystrophy (1), chronic weight management (1), cirrhotic cardiomyopathy (1), and colorectal cancer (1). Drug trials account for the largest share of new studies, with 11 new drug trials, followed by 1 biological trial, 1 device trial, 1 other type, and 1 procedure trial.

Opportunities for Healthy Volunteers

For individuals without a specific medical condition, there are opportunities to contribute to research. Of the 17 new trials launched this month, 1 is actively seeking healthy volunteers. Across Nashville, a total of 74 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Nashville's Leading Research Facilities

Nashville is home to several leading research institutions that consistently run a high volume of clinical trials. These facilities are key destinations for individuals seeking to participate in medical research:

• Vanderbilt University Medical Center (321 trials)
• SCRI Oncology Partners (113 trials)
• Vanderbilt University/Ingram Cancer Center (94 trials)
• Sarah Cannon Research Institute (66 trials)
• Tennessee Oncology (53 trials)
• Vanderbilt University (50 trials)
• Research Site (46 trials)
• Vanderbilt-Ingram Cancer Center (39 trials)
• The Children's Hospital at TriStar Centennial (27 trials)
• Vanderbilt Breast Center at One Hundred Oaks (16 trials)
• Monroe Carell Jr. Children's Hospital at Vanderbilt (13 trials)
• Tennessee Oncology, PLLC (13 trials)

These institutions offer a broad spectrum of research, with Vanderbilt University Medical Center and its affiliated cancer centers leading in oncology and diverse medical fields. SCRI Oncology Partners and Sarah Cannon Research Institute also play significant roles in cancer research.

Impending Deadlines for Key Health Areas

Patients managing specific health conditions also face impending deadlines to join research. Trials focused on various cancers and other conditions are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Breast cancer (4 trials)
• Prostate cancer (3 trials)
• Pancreatic cancer (2 trials)
• HIV infections (2 trials)
• Leukemia, myeloid, acute (2 trials)
• Ovarian cancer (2 trials)
• Autonomic failure (2 trials)
• Advanced malignant neoplasm (2 trials)
• Cardiovascular diseases (2 trials)
• Colorectal cancer (2 trials)

Broadening Your Search: Nearby Options

While Nashville offers a vast array of clinical trial opportunities, individuals may also find options in nearby communities within Tennessee. Cities with active trials include Memphis (9 trials), Knoxville (6 trials), Kingsport (2 trials), Tullahoma (2 trials), Chattanooga (2 trials), Franklin (1 trial), Martin (1 trial), and Elizabethton (1 trial).

Participation in clinical trials is open to a diverse range of individuals. Of the 17 new trials launched this month, 16 include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. Additionally, 2 new trials include children, and 1 is male-only. Academic institutions continue to play a vital role in Nashville's research ecosystem, with Vanderbilt University Medical Center sponsoring 4 new studies. Industry sponsors like Kallyope Inc. (2 trials), AstraZeneca (1 trial), and Merck Sharp & Dohme LLC (1 trial) are also driving significant research efforts.

As we move through June, Nashville's robust research community will continue to drive medical innovation, offering diverse opportunities for individuals to contribute to the future of healthcare.